Search for European Projects

24 European Projects Found

Searched on 125080 European Projects

 FINISHED 

Ultra-low dose of IL-2 for the treatment of recently diagnosed type 1 diabetes (DIABIL-2)

Start date: Oct 1, 2012, End date: Mar 31, 2019,

ConceptThe discovery of regulatory T cells (Tregs) has revolutionized our understanding of autoimmune diseases. As T1D is caused by the failure of Tregs to block autoimmune destruction of pancreatic ß-cells, Treg stimulation has the potential to stop the process, preserve ß-cells’ insulin secretion, and likewise prevent or delay disease progression and improve clinical outcome for patients.Backgro ...
Read Project

 7

 FINISHED 

Global Mapping of Synthetic Genetic Interactions in Drosophila (SYNGENE)

Start date: Aug 1, 2012, End date: Jul 31, 2018,

The genetics underlying phenotype-genotype relationships during development and disease is often complex with many genes contributing to a particular phenotypic outcome. While forward genetic screens have uncovered many mutations that are limiting at a particular stage or tissue, the majority of genes in most genomes remain genetically untouched. Recent studies in model organisms, in particular in ...
Read Project

 1

 FINISHED 

Gene Therapy for X-linked Chronic Granulomatous Disease (CGD) (NET4CGD)

Start date: Dec 1, 2012, End date: May 31, 2018,

This project is focused on the clinical development of a new orphan drug that can rapidly become a new treatment option for patients with the X-linked form of chronic granulomatous disease (X-CGD). This rare primary immune deficiency of phagocytes is caused by mutations in the gp91phox gene. Affected patients are highly-susceptible to infections and develop inflammatory granulomas. Several member ...
Read Project

 11

 FINISHED 

Deciphering the regulatory T cell repertoire: towards biomarkers and biotherapies for autoimmune diseases (TRIPOD)

Start date: May 1, 2013, End date: Apr 30, 2018,

...ion, (ii) to discover biomarkers for AIDs, and (iii) to develop therapies based on engineered Tregs.Deep sequencing of TCRs from insulin- and myelin-specific Tregs generated in vitro will identify dominant TCRs and antigen-specific Treg signatures. These will be analysed during thymocyte differentiation, at steady state and during disease progression, in mice and humans. Their potential as biomark ...
Read Project

 2

 FINISHED 

PIVOTAL ASSESSMENT OF THE EFFECTS OF BIOACTIVES ON HEALTH AND WELLBEING. FROM HUMAN GENOMA TO FOOD INDUSTRY - PATHWAY (PATHWAY-27)

Start date: Feb 1, 2013, End date: Jan 31, 2018,

...s and research must focus on bioactive-enriched foods (BEF), if consumer demands for foods delivering appropriate health and wellbeing benefits are to be fulfilled.PATHWAY, a pan-European interdisciplinary team of 16 life/social scientists and 10 high tech/ food processing SMEs, uniquely addresses the role and mechanisms of action of 3 bioactives (docosahexaenoic acid, β-glucan, anthocyanins, chos ...
Read Project

 28

 FINISHED 

Phase I/II Gene Therapy Trial of Fanconi anemia patients with a new Orphan Drug consisting of a lentiviral vector carrying the FANCA gene: A Coordinated International Action (EUROFANCOLEN)

Start date: Jan 1, 2013, End date: Dec 31, 2017,

Fanconi anemia (FA) is a rare inherited syndrome characterized by the early development of bone marrow failure and increasing predisposition to cancer with age. Allogeneic hematopoietic cell transplantation (alloHCT) is the only curative therapy for hematopoietic manifestations of FA, although associated with complications arising from myeloablation, graft versus host disease and increased inciden ...
Read Project

 13

 FINISHED 

Early warning signals of ageing in human stem cells and age-related disorders (SYSTEMAGE)

Start date: Jan 1, 2013, End date: Dec 31, 2017,

The regenerative power of a living organism is linked to the potential of its stem cells to replace the corresponding damaged tissue. Therefore organisms are as old as their stem cells. Whereas the vulnerability to cancer and chronic inflammation is associated with a decline of the immune system, the latter is in turn a sum product of interactions among hematopoietic stem cells (HSC), endothelial ...
Read Project

 11

 FINISHED 

Systems medicine of chronic inflammatory bowel disease (SYSMEDIBD)

Start date: Dec 1, 2012, End date: Nov 30, 2017,

...s. The aim is to build an experimentally validated model the NfkB oscillation in 4D within the gut tissue. Dynamic, experimental validation will be done for various types of cells in the gut by a combination of methods, including single-cell based transcriptomics, multi-photon microscopy and time-dependent, multi-component profiling. The validated model framework will enable searching for critical ...
Read Project

 13

 FINISHED 

Generating self-antigen diversity in the thymus: from gene expression patterns in single cells to the system level, an integrative approach (SELF-TOLERANCE)

Start date: Jun 1, 2012, End date: Nov 30, 2017,

...cell development a highly diverse T cell receptor repertoire is probed against a matching array of self-antigens. While the generation of the T cell receptor repertoire relies on unique genetic recombination mechanisms, the corresponding molecular principles underlying the generation of TCR ligands - self-peptide/MHC complexes - are less well understood; recent data indicate that novel principles ...
Read Project

 1

 FINISHED 

Quantitative T cell Immunology (QuanTI)

Start date: May 1, 2013, End date: Apr 30, 2017,

...unological data poses a challenge that cannot be successfully managed by immunologists, mathematicians, computer scientists or physicists on their own. QuanTI will provide an excellent multi-disciplinary and inter-sectorial research environment to train a new generation of quantitative immunologists.The propose ITN will strongly advance the development of new quantitative concepts to characteris ...
Read Project

 12

 FINISHED 

Mechanism-Based Integrated Systems for the Prediction of Drug-Induced Liver Injury (MIP-DILI)

Start date: Feb 1, 2012, End date: Jan 31, 2017,

The current test systems employed by Industry are poorly predictive for Drug induced liver injury (DILI). The ‘MIP-DILI’ project will address this situation by the development of innovative preclinical test systems which are both mechanism-based and of physiological, pharmacological and pathological relevance to DILI in humans. An iterative, tiered approach with respect to test compounds, test sys ...
Read Project

 29

 FINISHED 

Towards clinical translation of new gene targeting technologies for correcting inherited mutations and empowering adoptive immunotherapy of cancer (SUPERSIST)

Start date: May 1, 2013, End date: Oct 31, 2016,

Substantial evidence supports the therapeutic potential of ex vivo gene therapy based on Hematopoietic Stem Cell (HSC) or T lymphocytes to treat inherited diseases or cancer. Yet, the intrinsic limitations of current gene replacement approaches based on semi-randomly integrating vectors, and the occurrence in some clinical trials of severe adverse events related to gene transfer, prevent safe depl ...
Read Project

 5

 FINISHED 

ASSET: Analysing and Striking the Sensitivities of Embryonal Tumours (ASSET)

Start date: Nov 1, 2010, End date: Apr 30, 2016,

Cancer is hallmarked by multiple genetic aberrations that lead to a functional derangement of cellular signalling networks. Embryonal tumours (ETs) comprising neuroblastoma, medulloblastoma and Ewing sarcoma, occur early in life, and thus may reveal pathogenetically relevant lesions clearer than adulthood tumours which carry passenger mutations accumulated during life. ASSET will exploit this fact ...
Read Project

 20

 FINISHED 

EPIC-CVD: Individualised CVD risk assessment: tailoring targeted and cost-effective approaches to Europe's diverse populations (EPIC-CVD)

Start date: Jan 1, 2012, End date: Dec 31, 2015,

...sideration across Europe of risk scores with information on the interplay of nature and nurture together with biomarkers of lifestyle, biological pathways, vascular injury, and ageing.Our multidisciplinary consortium involves world-leading expertise in population health science, laboratory science (including VITAS, an SME partner, renowned for nutritional biomarker assays), translational science, ...
Read Project

 33

 FINISHED 

Detection of endpoints and biomarkers of repeated dose toxicity using in vitro systems (DETECTIVE)

Start date: Jan 1, 2011, End date: Dec 31, 2015,

"Assessment of repeated dose toxicity is a standard requirement in human safety evaluation and relies on animal testing as no alternatives are currently accepted for regulatory purposes. An integrated research strategy for the replacement of animal tests needs to comprise the development of biomarkers of long-term toxicity in human target cells. To this aim, the DETECTIVE project will set up a scr ...
Read Project

 15

 FINISHED 

Genetically defined and selectively mast cell-deficient mouse model to unravel the immunological roles of mast cells (MAST-CELL-FUNCTIONS)

Start date: Dec 1, 2009, End date: Nov 30, 2015,

Mast cells (MC) are best known for their central role in allergic disease but, more recently, MC have also been considered as important elements of the immune system in general. Since the original recognition, more than 10 years ago, that MC may have immunological functions beyond allergic disease, a very long list of physiological and pathological conditions has been accumulated in which MC have ...
Read Project

 1

 FINISHED 

Development of a therapeutic HPV vaccine via target epitope identification by mass spectrometry (THERAVAC)

Start date: Dec 1, 2011, End date: Nov 30, 2015,

...igh-risk human papillomavirus (HPV) types cause over 500.000 cancer cases per year, rendering HPV the #2 human carcinogen after tobacco. Infection-related tumors are attractive targets for cancer vaccination, as they provide the opportunity to target antigens that are immunological non-self. Vaccination can be prophylactic, inducing immune responses preventing infection in the first place, or ther ...
Read Project

 1

 FINISHED 

Amino acid sensing by TOR (TOR-AA)

Start date: Sep 1, 2010, End date: Aug 31, 2015,

The kinase TOR is a key regulator of cell growth and organismal metabolism in animals. Consequently, the correct regulationof TOR activity is important both for normal development and for disease. For instance, TOR is hyperactivated in almost allhuman cancers, and reduced TOR activity is associated with leanness and resistance to obesity. TOR activity is regulatedby a number of inputs including, i ...
Read Project

 1

 FINISHED 

Infrastructure for Systems Biology - Europe (ISBE)

Start date: Aug 1, 2012, End date: Jul 31, 2015,

The Infrastructure for Systems Biology in Europe (ISBE) programme comprises an infrastructure that is designed to meet the needs of European systems biology, in terms of development, applications and training. In order to address this requirement, we are proposing a distributed, interconnected infrastructure which primarily comprises three types of centres: Data Integration Centres (DICs), and sys ...
Read Project

 24

 FINISHED 

The role of noncoding RNA in sense and antisense or orientation in epigenetic control of rRNA genes (Ribogenes)

Start date: Mar 1, 2009, End date: Feb 28, 2014,

...k has revealed that NoRC, a chromatin remodeling complex that triggers heterochromatin formation and transcriptional silencing of a fraction of rRNA genes, is associated with 100-250 nt RNAs that originate from the intergenic spacer (IGS) separating rDNA repeats. Furthermore, a fraction of rDNA is transcribed in antisense orientation. Both IGS RNA and antisense transcripts display a growth- and ti ...
Read Project

 1

 FINISHED 

The DNA damage response pathway in MYCN amplified neuroblastoma (DDR-MYCN-NB)

Start date: Jan 1, 2012, End date: Dec 31, 2013,

...e stem from different sources and activate distinct pathways. However, they converge on the same components of the cell cycle machinery in the G1 phase of the cell cycle, namely the cyclin dependent kinases. To investigate the mechanisms that MYC proteins affect the G1 checkpoint, we propose to use neuroblastoma with deregulated MYCN expression as a paradigm to examine the mechanisms that MYC pro ...
Read Project

 1

 FINISHED 

Systems Biology of T-cell Activation in Health and Disease (SYBILLA)

Start date: Apr 1, 2008, End date: Sep 30, 2013,

...ystems-level insights, which would provide concepts of how to modulate T-cell activation. The SYBILLA project groups 14 partners from 9 different EU countries, including 3 SMEs. Through a multidisciplinary effort it aims to understand at the systems’ level, how T-cells discriminate foreign from auto-antigens. Towards this goal, a transgenic mouse system will be used as a tractable physiological mo ...
Read Project

 22

 FINISHED 

A SOCIAL COLLABORATIVE WORKING SPACE SEMANTICALLY INTERLINKING BIOMEDICAL RESEARCHERS, KNOWLEDGE AND DATA FOR THE DESIGN AND EXECUTION OF IN-SILICO MODELS AND EXPERIMENTS IN CANCER CHEMOPREVENTION (GRANATUM)

Start date: Feb 1, 2011, End date: Jul 31, 2013,

...dology that constitutes a step-by-step cookbook with methodological adoption guidelines for leveraging the quality of the integrative biomedical research in cancer chemoprevention; - Wide-scale dissemination and exploitation of the project results to the European academic, scientific and industrial stakeholders in the enlarged Europe and beyond. Led by Fraunhofer FIT, the GRANATUM consortium consi ...
Read Project

 7

 FINISHED 

Function of Non-coding RNAs in Lung Cancer (ncRNALungCancer)

Start date: Jul 1, 2009, End date: Jun 30, 2013,

...s in cancer and elucidate their potential as disease markers. In parallel, it allows us to broaden our research focus which would be impossible without this funding and delve into one of the most fascinating fields in RNA biology as well as establish lasting collaborations with outstanding laboratories in the USA and facilitate the integration into the research community in Europe.
Read Project

 1